Micreos’ Alternative to Antibiotics Secures Next €25 Million
Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas. This technology enables - for the first time - targeted killing of only the unwanted bacteria, regardless of resistance.
The funding comprises growth capital for Gladskin, the company’s specialized skincare brand, for people suffering from inflammatory skin conditions such as acne, eczema and rosacea. Last year Gladskin already helped hundreds of thousands of people in Europe and the USA, many of them experiencing a life-changing impact.
Proceeds are also earmarked for Micreos’ pharmaceutical program. This includes the clinical development of endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with the presence of S. aureus bacteria on the skin.
Over the past year Micreos separated its Pharmaceutical business from its ‘Over the Counter’ Consumer Health business. Micreos CEO Mark Offerhaus: “With this restructuring we align business and market requirements, enabling each business to pursue its own growth strategy. This is especially important for the pharmaceutical business, which is capital intensive and which we consider extremely promising. Direct investments in the Micreos Pharma, headed by Matt Regan, will now be possible.’’
Endolysins
Endolysins are naturally occurring enzymes that have the ability to target only harmful bacteria, while preserving the beneficial ones that form an important part of our natural defense, often referred to as our microbiome. Endolysins are safe and environmentally friendly. Because of their working mechanism, development of resistance is not expected and antibiotic resistance is not relevant.
Micreos
Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative for antibiotics. The group has pioneered the development of this technology and brought the world the first endolysin-based precision antibacterials.
The group’s head office is based in The Hague, NL. Micreos Pharmaceuticals has headquarters in Zug, CH, a Discovery and Technology Center in Wädenswil, CH, and a Development Team in Bilthoven, NL. Gladskin is based in the Netherlands, with offices in the USA, Germany, France and the UK. Micreos Food Safety is based in Wageningen, NL and markets FDA-and USDA-approved PhageGuard products against food pathogens such as Listeria, Salmonella and E. coli for food processing companies in the meat & poultry, fish, cheese and fresh produce industry. Micreos maintains a long-term collaboration with the Swiss Federal Technology Institute ETH in Zürich.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005513/en/
Contact information
Maarten van Dun
Director Corporate Communication Micreos
(m.vandun@micreos.com)
+31-681-028-274
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom